LitAlert ~~ GeneLit.com

    • Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents.
    • Martorana F, Da Silva LA, Sessa C, Colombo I.
    • Cancers (Basel). 2022 Feb 14;14(4):953. doi: 10.3390/cancers14040953.

    • Durable Disease-Free Survival in a Patient with Metastatic Triple-Negative Breast Cancer Treated With Olaparib Monotherapy.
    • Wang XW, Hu N, Cui L, Si Y, Yue J, Zheng F, Kang Y, Yuan P.
    • Curr Cancer Drug Targets. 2022 Feb 14. doi: 10.2174/1568009622666220214092207. Epub ahead of print.
    • Case report

    • Therapeutic Targeting of DNA Damage Response in Cancer.
    • Choi W, Lee ES.
    • Int J Mol Sci. 2022 Feb 1;23(3):1701. doi: 10.3390/ijms23031701.

    • Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2.
    • Samuel D, Diaz-Barbe A, Pinto A, Schlumbrecht M, George S.
    • Cells. 2022 Feb 4;11(3):539. doi: 10.3390/cells11030539.

    • Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC.
    • Ferrari P, Scatena C, Ghilli M, Bargagna I, Lorenzini G, Nicolini A.
    • Int J Mol Sci. 2022 Jan 31;23(3):1665. doi: 10.3390/ijms23031665.